|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Apexian_Pharmaceuticals
gptkb:Prothera_Biologics
gptkb:Prothera_Biologics,_Inc.
Apexian Pharmaceuticals, Inc.
Prothera Biologics, LLC.
|
|
gptkbp:awards
|
Best Places to Work
Innovative Company Award
Top 100 Biotech Companies
Fastest Growing Companies
|
|
gptkbp:ceo
|
gptkb:Jon_P._Stonehouse
|
|
gptkbp:clinical_trial
|
BC X10013
BC X1942
BC X9250
BC X9930
|
|
gptkbp:collaborations
|
gptkb:Duke_University
gptkb:University_of_Alabama_at_Birmingham
gptkb:Cure_Duchenne
|
|
gptkbp:focus
|
rare diseases
|
|
gptkbp:founded
|
gptkb:1986
|
|
gptkbp:founder
|
gptkb:Jon_P._Stonehouse
|
|
gptkbp:headquarters
|
gptkb:Birmingham,_Alabama
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Bio Cryst Pharmaceuticals
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:investment
|
gptkb:$5_million
$10 million
$25 million
$50 million
$100 million
|
|
gptkbp:key_people
|
gptkb:Jon_P._Stonehouse
gptkb:William_P._Sheridan
|
|
gptkbp:partnership
|
gptkb:GSK
gptkb:temple
gptkb:Johnson_&_Johnson
gptkb:Sanofi
gptkb:Shionogi
gptkb:Bristol-Myers_Squibb
gptkb:Pfizer
gptkb:Merck_&_Co.
gptkb:Roche
gptkb:Amgen
gptkb:Sarepta_Therapeutics
gptkb:Novartis
|
|
gptkbp:products
|
gptkb:Berotralstat
gptkb:Galidesivir
gptkb:Peramivir
BC X7353
|
|
gptkbp:research_focus
|
antiviral drugs
enzyme inhibitors
|
|
gptkbp:subsidiary
|
gptkb:Bio_Cryst_Pharmaceuticals,_Inc.
|
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
|
gptkbp:website
|
www.biocryst.com
|
|
gptkbp:bfsParent
|
gptkb:Peramivir
|
|
gptkbp:bfsLayer
|
5
|